Persistent URL of this record https://hdl.handle.net/1887/111630
In Collections
This item can be found in the following collections:
![GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
- All authors
- Braun, J.; Heijde, D. van der; Deodhar, A.; Diekman, L.; Sieper, J.; Kim, S.I.; Beutler, A.; Mack, M.; Xu, S.; Zrubek, J.; Hsu, B.; Inman, R.; GO-RAISE Investigators
- Date
- 2010-08-31
- Title of host publication
- Clinical and Experimental Rheumatology
- Volume
- 28
- Issue
- 4
- Pages
- 618 - 618